Article Text

PDF
SAT0387 “do not do” recommendations in the management of comorbidity in patients with axial spondyloarthritis. gecoax project
  1. JC Torre-Alonso1,
  2. C González2,
  3. S Castañeda3,
  4. R Curbelo4,
  5. E Collantes5,
  6. MV Hernández6,
  7. A Urruticoechea-Arana7,
  8. JC Nieto2,
  9. J García8,
  10. MΆ Abad9,
  11. J Ramírez6,
  12. C Suárez10,
  13. R Dalmau11,
  14. MD Martín-Arranz12,
  15. L Leόn13,
  16. JC Hermosa14,
  17. JC Obaya15,
  18. T Otόn4,
  19. L Carmona4
  1. 1Rheumatology, HU Monte Naranco, Oviedo
  2. 2Rheumatology, HU Gregorio Marañόn
  3. 3Rheumatology, HU la Princesa, IIS-IP
  4. 4InMusc, Madrid
  5. 5Rheumatology, HU Reina Sofía, Cόrdoba
  6. 6Rheumatology, HU Clinic i Provincial, Barcelona
  7. 7Rheumatology, H Can Misses, Ibiza
  8. 8Rheumatology, HU 12 de Octubre, Madrid
  9. 9Rheumatology, H de Plasencia, Plasencia
  10. 10Internal Medicine, HU la Princesa, IIS-IP
  11. 11Cardiology
  12. 12Gastroenterology, HU la Paz
  13. 13Psychology, UCJC, Madrid
  14. 14Centro de Salud Ciudades, Getafe
  15. 15Centro de Salud Alcobendas, Alcobendas, Spain

Abstract

Background During the development of recommendations and implementation aids of the GECOAx project, the importance of avoiding certain situations was highlighted.

Objectives To recognize what prescriptions, risk assessments, or preventive strategies are wrong practices and should thus be avoided in clinical practice. To establish not to do recommendations in the management of the comorbidity of AxSpA.

Methods A multidisciplinary group was selected [10 rheumatologists, 1 internist, 1 cardiologist, 1 gastroenterologist, 1 psychologist and 2 family physicians]. With the support of 3 methodologists, and after interactions aimed to edit a document for the management of comorbidity launched by the same panel, a list of Not to do recommendations was issued. In a discussion meeting, evidence was provided to support the recommendations, items without sufficient basis were removed, and the final list was produced.

Results A summary list of Not to do recommendations (Table 1) was issued.

Table 1

Conclusions These recommendations aim to avoid making common mistakes in clinical practice and to help better management of frequent comorbidity in patients with AxSpA.

Acknowledgements This project was funded by Merck Sharp & Dohme Spain. Merck Sharp & Dohme had no influence on either the development of the project or the final content of the manuscript.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.